Dhanvantri Jeevan Rekha (BOM:531043) EBIT: ₹4.0 Mil (TTM As of Mar. 2026)


BOM:531043 Dhanvantri Jeevan Rekha Ltd BOM:531043
56 GF Score
Price ₹26.45
GF Value ₹24.87
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Dhanvantri Jeevan Rekha EBIT?

Dhanvantri Jeevan Rekha BOM:531043 -3.50% 56 EBIT is ₹4.0 Mil as of Mar. 2026. GuruFocus rates BOM:531043 with a GF Score™ of 56/100 and a GF Value™ of ₹24.87 (Fairly Valued). The stock has 3 warning signs investors should review.

Dhanvantri Jeevan Rekha's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹3.0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹4.0 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Dhanvantri Jeevan Rekha's annualized ROC % for the quarter that ended in Mar. 2026 was 5.06%. Dhanvantri Jeevan Rekha's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 14.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Dhanvantri Jeevan Rekha's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 5.60%.


Dhanvantri Jeevan Rekha  (BOM:531043) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Dhanvantri Jeevan Rekha's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=8 * ( 1 - 0% )/( (0 + 158)/ 1 )
=8/158
=5.06 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Dhanvantri Jeevan Rekha's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=12/( ( (0 + max(0, 0)) + (85.7 + max(-28, 0)) )/ 1 )
=12/( ( 0 + 85.7 )/ 1 )
=12/85.7
=14.00 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(26.2 + 0.8 + 0) - (8.7 + 0 + 46.3)
=-28

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Dhanvantri Jeevan Rekha's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=4/71.403
=5.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dhanvantri Jeevan Rekha EBIT Related Terms


Dhanvantri Jeevan Rekha EBIT Historical Data

* Premium members only.

The historical data trend for Dhanvantri Jeevan Rekha's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dhanvantri Jeevan Rekha EBIT Chart

Dhanvantri Jeevan Rekha Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.75 -1.44 2.56 5.70 4.10

Dhanvantri Jeevan Rekha Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.60 -1.40 1.80 3.00

BOM:531043 vs HCA, THC, DVA: EBIT Comparison

For the Medical Care Facilities subindustry, Dhanvantri Jeevan Rekha's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dhanvantri Jeevan Rekha EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Dhanvantri Jeevan Rekha's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Dhanvantri Jeevan Rekha's EV-to-EBIT falls into.


BOM:531043
56GF Score
Dhanvantri Jeevan Rekha Ltd BOM:531043
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dhanvantri Jeevan Rekha EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹4.0 Mil mean?
Dhanvantri Jeevan Rekha (BOM:531043) has a EBIT of ₹4.0 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dhanvantri Jeevan Rekha.
Is Dhanvantri Jeevan Rekha's EBIT too high?
Dhanvantri Jeevan Rekha's current EBIT is ₹4.0 Mil. Overall, Dhanvantri Jeevan Rekha has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dhanvantri Jeevan Rekha's EBIT compare to HCA and THC?
Dhanvantri Jeevan Rekha's EBIT of ₹4.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Dhanvantri Jeevan Rekha. Dhanvantri Jeevan Rekha's current EBIT is ₹4.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dhanvantri Jeevan Rekha stock overvalued right now?
Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha (BOM:531043) is currently considered Fairly Valued. The stock's GF Value™ is ₹24.87, compared to a current price of ₹26.45 — trading 6.4% above its estimated fair value. The current EBIT is ₹4.0 Mil. Dhanvantri Jeevan Rekha's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Dhanvantri Jeevan Rekha (BOM:531043), the current EBIT is ₹4.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dhanvantri Jeevan Rekha (BOM:531043) Overvalued in 2026?

Based on GuruFocus' analysis, Dhanvantri Jeevan Rekha stock appears to be overvalued. The current stock price of ₹26.45 is trading 6.4% above its estimated GF Value™ of ₹24.87. GuruFocus considers Dhanvantri Jeevan Rekha to be Fairly Valued.

Key valuation signals for BOM:531043:

  • EBIT: ₹4.0 Mil
  • GF Value™: ₹24.87 vs. price of ₹26.45 (6.4% above fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the BOM:531043 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dhanvantri Jeevan Rekha Business Description

Address No. 1 Saket, Meerut, UP, IND, 250003
Dhanvantri Jeevan Rekha Ltd is engaged in providing diagnostic and therapeutic services and has extended its scope of diagnostic and hospital services by providing a fully operational Cath Lab, catering to higher end needs of the cardiac patients including Angiography, Angioplasty, Pacemaker Implantation, Valvuloplasty etc. The hospital has expanded its services to include a wide range of specialties such as Cardiology, Neurology, Orthopedics, Radiology, Gastroenterology, General Surgery, Urology, and General Medicine.
56GF Score

Get the complete analysis for BOM:531043

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹26.45
Price
₹24.87
GF Value